Ingibitory SGLT-2: farmakologicheskaya glyukozuriya kak novyy podkhod v upravlenii SD 2 tipa
- Autores: Demidova T.Y.1
-
Afiliações:
- Edição: Nº 5 (2015)
- Páginas: 12-19
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287805
- ID: 287805
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Progressive course of type 2 diabetes mellitus, the lack of an «ideal» drug for the treatment of this disease are a key factors for the searching of new opportunities for effective management of blood glucose. The emergence of a new class of oral antidiabetic drugs is always an outstanding event in the modern diabetology The appearance of sodium-glucose co-transporter type 2 inhibitors and their introduction into clinical practice open a new era in the treatment of diabetes. Dapagliflozin is the first representative of this class, registered in Russia. With the best risk/benefit ratio and unique insulin-independent mechanism of action, dapagliflozin provides new opportunities to control not only the level of glycemia, but body weight without increasing the risk of hypoglycemia both foe physicians and patients.
Texto integral
Bibliografia
- International Diabetes Federation. IDF Diabetes Atlas update poster, 6th edn. Brussels: International Diabetes Federation, 2014.
- US Department of Health and Human Services, National Diabetes Information Clearinghouse. National Diabetes Statistics, 2007. NIH Publication № 08-3892. http://diabetes.niddk. nih.gov/dm/pubs/statistics/DM_Statistics.pdf. Last updated: June 2008. Accessed October 19, 2010.
- DeFronzo R.A., Davidson J.A., Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 2012;14(1):5-14.
- Mather A., Pollock C. Glucose handling by the kidney. Kidney Int. Suppl. 2011; (120): S1-6.
- Покровский В.М., Коротько Г.Ф. Физиология человека. М.: Медицина, 2007.
- Cheung K.L., Lafayette R.A. Renal Physiology of Pregnancy. Adv. Chronic Kidney Dis. 2013;20(3):209-14.
- Ehrenkranz J.R.L, Lewis N.G., Kahn C.R., Roth J. P hlorizin: a review. Diabetes Metab. Rev. 2005;21:31-8.
- Инструкция по медицинскому применению лекарственного препарата Форсига® (таблетки, покрытые пленочной оболочкой, 5 мг, 10 мг). Регистрационное удостоверение ЛП-002596 от 21/08/2014.
- Forxiga. EMA. http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/ medicines/002322/human_med_001546. jsp&mid
- FDA approves Farxiga to treat type 2 diabetes. U.S. Food and Drug Administration. http:// www.fda.gov/newsevents/newsroom/pressan-nouncements/ucm380829.htm
- Ferrannini E.,Ramos S.J.,Salsali A.,Tang W.,List J.F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-24.
- Bailey C.J., Gross J.L., Pieters A., Bastien A., List J.F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycae-mic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-33.
- Bailey C.J., Gross J.L., Hennicken D., Iqbal N., Mansfield T.A., List J. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, doubleblind, placebo-controlled 102-week trial. BMC Medicine. 2013;11:43.
- Nauck M.A., Del Prato S., Meier J.J., Duran-Garcia S., Rohwedder K., Elze M., Parikh S.J. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-22.
- Nauck M.A., Del Prato S., Duran-Garcia S., Rohwedder K., Langkilde A.M., Sugg J., Parikh S.J. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes. Metab. 2014;16(11): 1111-20.
- Henry R.R., Murray A.V., Marmolejo M.H., Hennicken D., Ptaszynska A., List J.F. Dapaglifl ozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int. J. Clin. Pract. 2012; 66(5):446-56.
- Pucino F. Clinical review. Division of metabolism and endocrinology products. Application number: 202293Orig1s000. Center for drug evaluation and research, 2009.
- Ptaszynska A., Johnsson K.M., Parikh S.J., de Bruin T.W., Apanovitch A.M., List J.F. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014; 37:815-29.
Arquivos suplementares
